 MOUNTAIN VIEW, Calif., March 10, 2021 GLOBE NEWSWIRE -- Iridex Corporation NASDAQ: IRIX, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with Topcon Corporation. Under the terms of the agreements, Topcon Corporation and its affiliates have completed the 10 million equity investment in Iridex and the purchase of exclusive distribution rights to the Iridex products in Asia Pacific and key EMEA regions, and Iridex has completed the purchase of assets related to PASCAL laser products. The total transaction results in a net amount of 19.5 million to Iridex. The transaction was announced on March 2, 2021. 